Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Colorectal Neoplasms 7Prostatic Neoplasms 6Diabetes Mellitus, Insulin-Dependent, 12 6Carcinoma, Non-Small-Cell Lung 6Carcinoma, Hepatocellular 6Melanoma 5Breast Neoplasms 5Squamous Cell Carcinoma of Head and Neck 4Neoplasms 4Small Cell Lung Carcinoma 3Recurrence 3Head and Neck Neoplasms 3Carcinoma, Renal Cell 3Urinary Bladder Neoplasms 2Recurrent Squamous Cell Lung Carcinoma 2Ovarian Neoplasms 2Mesothelioma 2Lung Neoplasms 2Liver Neoplasms 2Fallopian Tube Neoplasms 2Cholangiocarcinoma 2Biliary Tract Neoplasms 2Vascular Neoplasms 1Uterine Cervical Neoplasms 1Urothelial Cancer 1Thyroid Neoplasms 1Thyroid Cancer, Papillary 1Testicular Neoplasms 1Solid Tumor 1Sarcoma, Synovial 1

Interventions

Nivolumab 4pertuzumab 2pembrolizumab 2durvalumab 2Paclitaxel 2Docetaxel 2Capecitabine 2ulocuplumab 1tremelimumab 1tazarotene 1talazoparib 1romiplostim 1pexidartinib 1pamiparib 1onartuzumab 1magrolimab 1entrectinib 1cobimetinib 1atezolizumab 1Sunitinib 1Rifampin 1Ramucirumab 1Radiosurgery 1N-benzhydryl-5-(2-(methylamino)propanamido)-3-(3-methylbutanoyl)-6-oxodecahydropyrrolo(1,2-a)(1,5)diazocine-8-carboxamide 1Midazolam 1MK-4166 1LY3022855 1LY2510924 1LY-2157299 1Itraconazole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Solid Tumor × tremelimumab × Clear all
NCT02718911 2023-10-16

A Study of LY3022855 in Combination With Durvalumab or Tremelimumab in Participants With Advanced Solid Tumors

Eli Lilly and Company

Phase 1 Completed
72 enrolled 23 charts
Other solid neoplasm

Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡